Shorts Events Patient Resources Prescribing Information Previous Next MAKE PROTECTION YOUR SUPERPOWER Protect your patients who have cardio, renal, and metabolic conditions. Cardiology See all > Read more Christiane Angermann (Germany) | Ricardo Carvalho (Portugal) Clinical relationship between the heart and the kidneys Watch now Opens in new tab Read more Christiane Angermann (Germany) | Ricardo Carvalho (Portugal) Why is empagliflozin now a preferred heart failure treatment, coming from a history of diabetes? Watch now Opens in new tab Read more Christiane Angermann (Germany) | Ricardo Carvalho (Portugal) How has recent evidence and the ESC 2023 guidelines changed management of heart failure? Watch now Opens in new tab Nephrology Endocrinology See all > Read more Lee-Ling Lim (Malaysia) Expert opinion on reducing the risk of genital infections and UTIs when initiating SGLT2 inhibitors Watch now Opens in new tab Read more Lee-Ling Lim (Malaysia) Why is organ protection crucial in patients with cardiorenal metabolic conditions? Watch now Opens in new tab Read more Lee-Ling Lim (Malaysia) Reducing the risk of diabetic ketoacidosis when initiating SGLT2 inhibitors Watch now Opens in new tab Primary Care See all > Read more Christiane Angermann (Germany) | Ricardo Carvalho (Portugal) Clinical relationship between the heart and the kidneys Watch now Opens in new tab Read more Christiane Angermann (Germany) | Ricardo Carvalho (Portugal) Why is empagliflozin now a preferred heart failure treatment, coming from a history of diabetes? Watch now Opens in new tab Read more Christiane Angermann (Germany) | Ricardo Carvalho (Portugal) How has recent evidence and the ESC 2023 guidelines changed management of heart failure? Watch now Opens in new tab Home Shorts
Read more Christiane Angermann (Germany) | Ricardo Carvalho (Portugal) Clinical relationship between the heart and the kidneys Watch now Opens in new tab
Read more Christiane Angermann (Germany) | Ricardo Carvalho (Portugal) Why is empagliflozin now a preferred heart failure treatment, coming from a history of diabetes? Watch now Opens in new tab
Read more Christiane Angermann (Germany) | Ricardo Carvalho (Portugal) How has recent evidence and the ESC 2023 guidelines changed management of heart failure? Watch now Opens in new tab
Read more Lee-Ling Lim (Malaysia) Expert opinion on reducing the risk of genital infections and UTIs when initiating SGLT2 inhibitors Watch now Opens in new tab
Read more Lee-Ling Lim (Malaysia) Why is organ protection crucial in patients with cardiorenal metabolic conditions? Watch now Opens in new tab
Read more Lee-Ling Lim (Malaysia) Reducing the risk of diabetic ketoacidosis when initiating SGLT2 inhibitors Watch now Opens in new tab
Read more Christiane Angermann (Germany) | Ricardo Carvalho (Portugal) Clinical relationship between the heart and the kidneys Watch now Opens in new tab
Read more Christiane Angermann (Germany) | Ricardo Carvalho (Portugal) Why is empagliflozin now a preferred heart failure treatment, coming from a history of diabetes? Watch now Opens in new tab
Read more Christiane Angermann (Germany) | Ricardo Carvalho (Portugal) How has recent evidence and the ESC 2023 guidelines changed management of heart failure? Watch now Opens in new tab